Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease

Mocci, Giammarco; Marzo, Manuela; Papa, Alfredo; Armuzzi, Alessandro; Guidi, L.

doi:10.1016/j.crohns.2013.01.009

Cited by 118 publications

(93 citation statements)

References 109 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1 However, this is the first reported case of SDRIFE associated with infliximab to the best of our knowledge.…”

Section: Discussionmentioning

confidence: 72%

See 1 more Smart Citation

Symmetrical drug-related intertriginous and flexural exanthema (Baboon syndrome) associated with infliximab

Bulur¹,

Keseroglu²,

Saraçoğlu³

et al. 2015

J Dermatol Case Rep

View full text Add to dashboard Cite

Background: Symmetrical drug related intertriginous and flexural exanthema (SDRIFE or Baboon syndrome) is a symmetrical contact dermatitis on inverse regions of the body. The disorder is easily differentiated from other drug eruptions by its typical appearance and lack of other concurrent findings. Observation:A 50-year-old male patient presented to our clinic complaining of a rash that had developed two days after the tenth infliximab infusion for psoriasis and reoccurred after consecutive infusions. The physical examination revealed a bilateral intergluteal, inguinal, abdominal, axillary, antecubital and neck region macular erythematous rash. There were no other systemic findings. The laboratory values were within normal range. The patient was diagnosed with symmetrical drug-related intertriginous and flexural exanthema associated with infliximab treatment based on dermatological findings, histopathology and the results of the provocation test. The lesions resolved permanently after the patient was swiched from infliximab to adalimumab. Conclusion:Various cutaneous adverse events of anti-tumor necrosis factor alpha treatment have already been reported. The increased use of these agents can lead to a wider variety of drug-induced skin lesions, such as the reported Baboon syndrome.

show abstract

“…1 However, this is the first reported case of SDRIFE associated with infliximab to the best of our knowledge.…”

Section: Discussionmentioning

confidence: 72%

“…1 We report a patient with previously unreported symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) with remarkable cutaneous symptoms associated with infliximab treatment for chronic plaque psoriasis.…”

Section: Introductionmentioning

confidence: 99%

Symmetrical drug-related intertriginous and flexural exanthema (Baboon syndrome) associated with infliximab

Bulur¹,

Keseroglu²,

Saraçoğlu³

et al. 2015

J Dermatol Case Rep

View full text Add to dashboard Cite

show abstract

“…Drug induced skin lesions represent the most frequent side effect of anti-TNFα agents, presumably in susceptible individuals [3][4][5][6][7][8][9][10]. They include infusion/ injection site reactions, psoriasis and psoriasis-like lesions, lupus-like syndromes, vasculitis, cutaneous infections, eczematous reactions, lichenoid reactions, cutaneous lymphomas, skin cancers and granulomatous diseases [5][6][7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

“…They include infusion/ injection site reactions, psoriasis and psoriasis-like lesions, lupus-like syndromes, vasculitis, cutaneous infections, eczematous reactions, lichenoid reactions, cutaneous lymphomas, skin cancers and granulomatous diseases [5][6][7][8][9][10]. Many noninfectious cutaneous granulomatous reactions have been described in literature, such as granuloma annulare, cutaneous sarcoidosis and sarcoid-like granulomatosis [11,12].…”

Section: Introductionmentioning

confidence: 99%

Reactive Granulomatous Dermatitis during Anti-TNF Therapy: A Case Report and Review of the Literature

Cassone¹

2017

Clin Med Rev Case Rep

View full text Add to dashboard Cite

Tumor Necrosis Factor (TNF)-α blockers have been shown to be highly effective in the treatment of arthritis not responsive to traditional therapy. In parallel, there are an increasing number of reports about the development of cutaneous side effects after the administration of anti-TNF-α agents. Noninfectious cutaneous granulomatous reactions include granuloma annulare, non-caseating granuloma, sarcoid-like granulomatosis and also a wide spectrum of conditions recently unified under the term of reactive granulomatous dermatitis.The majority of the above reported granulomatous dermatitis is associated with an underlying inflammatory disorder, and almost all may be drug-induced. Moreover, a substantial overlap, both in clinical and histologic features, is present between these conditions. We describe a reactive granulomatous dermatitis in a patient with psoriatic arthritis treated with adalimumab, resolved after the TNF-α inhibitor discontinuation, and we summarize the recent case-reports in which reactive granulomatous dermatitis were observed in patients with arthritis receiving various TNF-α inhibitors. Reactive granulomatous dermatitis may be a possible long-term side effect of this class of drugs. Although TNF-α blockers are usually used in the treatment of granulomatous disorders, patients treated with these kinds of drugs should be carefully monitored as, in rare cases, TNF-α inhibitors may induce sufficient cytokine activation to support granuloma formation.

show abstract

“…This would enable the treating physician to directly introduce the patient to the best suited biological therapeutic option, which would enable a better and time-efficient control of disease for the patient. Reliable prediction of therapeutic response would also be essential in order to avoid exposure of non-responders to an inefficient biological therapy and associated potential side effects [16,17]. In view of current economic constraints in healthcare systems, the development of reliable predictors of response to these relatively expensive treatments is of central importance and might be essential to their future use.…”

Section: Introductionmentioning

confidence: 99%

Predicting Therapeutic Response by in vivo Molecular Imaging in Inflammatory Bowel Diseases

Atreya¹

2016

Dig Dis

View full text Add to dashboard Cite

Background: Different invasive and non-invasive imaging modalities are indispensable tools in the management of inflammatory bowel disease (IBD) patients. Standard imaging procedures like white light endoscopy or MRI are used to define gut inflammation based on structural changes and altered morphology of the mucosa. Nevertheless, it has thus far not been possible to analyse biological processes at the cellular level, which drive intestinal inflammation in IBD patients. The recent advent of molecular imaging in the field of IBD has opened new promising avenues to allow personalized medicine approaches based on in vivo-detected molecular findings. Key Messages: Recent clinical studies have attempted to address the issue of predicting therapeutic response to anti-tumor necrosis factor (TNF) treatment in IBD patients based on the molecular mechanism of action of these agents and corresponding in vivo assessment of mucosal immune responses. Several experimental studies have indicated that one of the main functions of efficacious anti-TNF therapy in IBD is the induction of intestinal cell apoptosis. Fittingly, a corresponding molecular-imaging study using single-photon emission CT for the localization and quantification of cell apoptosis, demonstrated that induction of mucosal T-cell apoptosis correlated with the therapeutic response to anti-TNF therapy in Crohn's disease patients. There was moreover a predictive capacity regarding therapeutic efficacy. As the main biological properties of anti-TNF antibodies in IBD are mediated through binding to membrane-bound TNF (mTNF) expressing intestinal cells, another study used molecular imaging for in vivo visualization of these cells via fluorescent anti-TNF antibodies to predict therapeutic efficacy of these agents. It could be shown that patients with high amounts of mTNF positive cells showed significantly better response rates compared to patients with low amounts of mTNF positive cells. Conclusion: In vivo molecular imaging in IBD has the potential to have an impact on our current treatment approaches and may allow us to individualize specific therapies based on molecular level analysis.

show abstract

Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease

Cited by 118 publications

References 109 publications

Symmetrical drug-related intertriginous and flexural exanthema (Baboon syndrome) associated with infliximab

Symmetrical drug-related intertriginous and flexural exanthema (Baboon syndrome) associated with infliximab

Reactive Granulomatous Dermatitis during Anti-TNF Therapy: A Case Report and Review of the Literature

Predicting Therapeutic Response by in vivo Molecular Imaging in Inflammatory Bowel Diseases

Contact Info

Product

Resources

About